-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) and its subsidiaries Suzhou Shengdia Biomedical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue “drug clinical trials” for HRS-2329 tablets, HRS 6093 tablets, SHR-9839 (sc), HRS-4642 injections, and adbelimab injections “Notice of Approval”. Clinical trials will be carried out in the near future.

Zhitongcaijing·11/18/2026 09:33:15
Listen to the news
Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) and its subsidiaries Suzhou Shengdia Biomedical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue “drug clinical trials” for HRS-2329 tablets, HRS 6093 tablets, SHR-9839 (sc), HRS-4642 injections, and adbelimab injections “Notice of Approval”. Clinical trials will be carried out in the near future.